MedTrace Logo

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

NCT06361979 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-12

No results posted yet for this study

Summary

This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases

Conditions

  • Breasr Cancer

Interventions

DRUG

SHR-A1811

SHR-A1811: intravenous

DRUG

Bevacizumab

Bevacizumab:intravenous

Sponsors & Collaborators

  • Huihua Xiong

    lead OTHER

Principal Investigators

  • Xiong huihua · Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2025-05-31
Completion
2026-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06361979 on ClinicalTrials.gov